22nd Century Group (XXII) Falls Following FDA Feedback on Very Low Nicotine MRTPA Filings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Chardan Capital Weighs in on 22nd Century Group (XXII) as FDA Responds to MRTP Application
January 5, 2017 12:56 PM ESTChardan Capital Markets analyst James McIlree weighed in on 22nd Century Group (NYSE: XXII) after the company company announced that the FDA has provided the Company with helpful and positive feedback on the Companys combined Modified Risk Tobacco Product Applications (MRTPAs) and Premarket Tobacco Product Applications (PMTAs) for 22nd Centurys BRAND A Very Low Nicotine tobacco cigarettes.
"We did not... More
